Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BOS 342

Next Previous
Drug Profile

BOS 342

Alternative Names: BOS-342; PRS-342

Latest Information Update: 17 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pieris
  • Developer Boston Pharmaceuticals; Palvella Therapeutics
  • Class Antibodies; Antineoplastics; Immunotherapies; Lipocalins; Recombinant fusion proteins
  • Mechanism of Action CD137 antigen agonists; Immunologic cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Liver cancer
  • No development reported Cancer

Most Recent Events

  • 13 Dec 2024 Pieris Pharmaceuticals has merged with Palvella Therapeutics to form Palvella Therapeutics
  • 11 Sep 2023 Phase-I clinical trials in Liver cancer (unspecified route) before September 2023 (Boston Pharmaceuticals pipeline, September 2023)
  • 28 Apr 2023 No recent reports of development identified for preclinical development in Cancer in Germany (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top